Loading...
0

Pulmonary Arterial Hypertension Treatment Market by Drug Type (Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, sGC Stimulators, and PDE-5 Dipsticks) and Sales Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2019-2026

LI_195470
Pages: NA
Nov 2019 | 25 Views
 
Author(s) : NA
Tables: NA
Charts: NA
 

Pulmonary arterial hypertension (PAH) is a form of condition known as pulmonary hypertension which means high level blood pressure in the lungs. PAH is characterized by an increase in pressure within the pulmonary arteries because of structural changes within vessel walls, aggregation of platelets and alteration of swish somatic cell function resulting into increasing pressure within the pulmonic arteries chargeable for pumping blood to the lungs. Change in routine of consumers in terms of lack of physical activity and more consumption of alcohol, tobacco, and fast food products increases the chances of developing hypertension and high blood pressure. The increased blood pressure in turn, gives rise to several diseases such as stroke and heart attacks. Treatment of pulmonary arterial hypertension can be done by using drugs such as endothelin receptor antagonists, prostacyclin and prostacyclin analogs, soluble guanylate cyclase stimulators, and phosphodiesterase type 5 inhibitor. 

Increase in launch of innovative drugs & treatment therapies, favorable initiatives such as rare disease act and orphan drug act by government, rise in prevalence of pulmonary arterial hypertension disease, increase in consumption of alcohol or tobacco, sedentary lifestyle, smoking, & other idiopathic conditions, increase in geriatric population, and increase in adoption of treatment & healthcare spending are the factors that drive the growth of the pulmonary arterial hypertension market. However, termination of drugs by major players during clinical trials, unawareness about the presence of pulmonary arterial hypertension among patients, and high diagnosis and treatment cost are expected to restrain the market growth. Expiry of patents of major PAH drugs leads to generic versions of these drugs being introduced in the market and being sold at 60% to 70% lower prices than that of the present branded drugs which is big challenge for the growth of pulmonary arterial hypertension treatment market.

The pulmonary arterial hypertension treatment market is segmented based on the drug type, sales channel, and region. Under the drug type segment, the market is classified into endothelin receptor antagonists ERAs, prostacyclin & prostacyclin analogs, sGC stimulators, and PDE-5 dipsticks. Endothelin receptor antagonists are further divided into bosentan, ambrisentan, and macitentan. Prostacyclin analogs are further categorized into epoprostenol, iloprost, and treprostinil. sGC stimulators include riociguat. PDE-5 dipsticks are further divided into sildenafil and tadalafil.  Based on sales channel, market is studied across hospital pharmacy, retail pharmacy, and online pharmacy. Based on region, the pulmonary arterial hypertension market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Some of major players operating in the pulmonary arterial hypertension treatment market include United Therapeutic Corporation, Eli Lilly and Company, Actelion Inc., GlaxoSmithKline plc. (GSK), Steady Med Ltd., Gilead Sciences, Inc., Pfizer Inc., Teva Pharmaceuticals Inc., Actelion Pharmaceuticals, Ltd., Novartis International AG, and Bayer AG.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and market forecast estimations from 2019 to 2026, which assists to identify the prevailing pulmonary arterial hypertension treatment market opportunities. 
  • An in-depth market analysis includes analysis of various regions and is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global market is provided.
  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current market trends and future market potential from 2019 to 2026 in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which helps understand competitive outlook of the global pulmonary arterial hypertension treatment market.  

KEY MARKET SEGMENTS

By Drug Type

  • Endothelin Receptor Antagonists (ERAs) 
    • Bosentan
    • Ambrisentan
    • Macitentan
    • Others
  • Prostacyclin and Prostacyclin Analogs
    • Epoprostenol
    • Iloprost
    • Treprostinil
    • Others
  • sGC Stimulators
    • Riociguat
  • PDE-5 Dipsticks
    • Sildenafil
    • Tadalafil

By Sales Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

  

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

REQUEST TOC/SAMPLE

Request Customization

REQUEST TOC/SAMPLE

OR

Purchase Full Report of
Pulmonary Arterial Hypertension Treatment Market

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370  $4,833
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,805
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $8,096
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
REQUEST TOC/SAMPLE

Buy Full Version
"Pulmonary Arterial Hypertension Treatment Market"
Purchase Enquiry